Cytosorbents - CTSO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $2.50
  • Forecasted Upside: 184.41%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.88
▲ +0.07 (8.65%)

This chart shows the closing price for CTSO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cytosorbents Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTSO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTSO

Analyst Price Target is $2.50
▲ +184.41% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Cytosorbents in the last 3 months. The average price target is $2.50, with a high forecast of $4.00 and a low forecast of $1.00. The average price target represents a 184.41% upside from the last price of $0.88.

This chart shows the closing price for CTSO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 polled investment analysts is to moderate buy stock in Cytosorbents. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$1.00N/A
12/29/2023HC WainwrightDowngradeBuy ➝ Neutral$5.50 ➝ $1.00Low
9/7/2023B. RileyInitiated CoverageBuy ➝ Buy$4.00Low
8/2/2023HC WainwrightReiterated RatingBuy ➝ Buy$5.50Low
3/10/2023HC WainwrightReiterated RatingBuy$5.50Low
11/4/2022HC WainwrightLower TargetBuy$9.00 ➝ $5.50Low
5/4/2022B. RileyLower Target$7.00 ➝ $6.00High
3/10/2022B. RileyLower Target$10.00 ➝ $7.00Medium
10/14/2021B. RileyInitiated CoverageBuyHigh
10/13/2021CowenLower TargetOutperform$14.00 ➝ $10.00High
10/10/2021SVB LeerinkReiterated RatingBuyLow
8/4/2021HC WainwrightReiterated RatingBuy$13.00High
1/4/2021B. RileyBoost TargetOutperform ➝ Buy$16.00 ➝ $17.00N/A
9/17/2020Jefferies Financial GroupInitiated CoverageBuy$15.00Medium
9/1/2020SVB LeerinkInitiated CoverageOutperform$15.00Medium
7/23/2020B. RileyReiterated RatingBuyLow
6/12/2020B. RileyInitiated CoverageBuy$16.00Medium
5/7/2020Maxim GroupInitiated CoverageBuy$14.00Low
5/6/2020HC WainwrightBoost TargetBuy$13.00 ➝ $14.00High
5/6/2020B. RileyBoost TargetBuy$12.00 ➝ $16.00High
4/16/2020HC WainwrightReiterated RatingBuy$13.00Low
3/26/2020Maxim GroupReiterated RatingBuy$8.00High
3/9/2020Dawson JamesReiterated RatingBuy$15.00 ➝ $17.00High
3/6/2020HC WainwrightReiterated RatingBuy$13.00Low
11/27/2019B. RileyReiterated RatingBuy$12.00Low
11/26/2019HC WainwrightReiterated RatingBuy$13.00High
11/25/2019Maxim GroupReiterated RatingBuy$8.00High
10/21/2019B. RileySet TargetBuy$10.00Low
8/7/2019HC WainwrightReiterated RatingBuyHigh
8/7/2019Maxim GroupSet TargetBuy$14.00High
7/19/2019B. RileySet TargetBuy$12.00N/A
5/8/2019Maxim GroupSet TargetBuy$14.00High
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/27/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/25/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/24/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/25/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/24/2024

Current Sentiment

  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Cytosorbents logo
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $0.88
Low: $0.80
High: $0.92

50 Day Range

MA: $0.94
Low: $0.79
High: $1.04

52 Week Range

Now: $0.88
Low: $0.78
High: $4.29

Volume

108,104 shs

Average Volume

156,206 shs

Market Capitalization

$47.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Cytosorbents?

The following Wall Street sell-side analysts have issued research reports on Cytosorbents in the last year: B. Riley, HC Wainwright, and StockNews.com.
View the latest analyst ratings for CTSO.

What is the current price target for Cytosorbents?

2 Wall Street analysts have set twelve-month price targets for Cytosorbents in the last year. Their average twelve-month price target is $2.50, suggesting a possible upside of 184.4%. B. Riley has the highest price target set, predicting CTSO will reach $4.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $1.00 for Cytosorbents in the next year.
View the latest price targets for CTSO.

What is the current consensus analyst rating for Cytosorbents?

Cytosorbents currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CTSO.

What other companies compete with Cytosorbents?

How do I contact Cytosorbents' investor relations team?

Cytosorbents' physical mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company's listed phone number is (732) 329-8885 and its investor relations email address is [email protected]. The official website for Cytosorbents is www.cytosorbents.com. Learn More about contacing Cytosorbents investor relations.